LH - Laboratory Corp of America Holdings Stock Price, Fair Value and News

206.52USD-1.45 (-0.70%)Delayed as of 24 Apr 2024, 11:39 am ET

Market Summary

USD206.52-1.45

Delayedas of 24 Apr 2024, 11:39 am

-0.70%

LH Alerts

3 major insider sales recently.

LH Stock Price

View Fullscreen

LH RSI Chart

LH Valuation

Market Cap

17.5B

Price/Earnings (Trailing)

41.87

Price/Sales (Trailing)

1.44

Price/Free Cashflow

20.02

LH Price/Sales (Trailing)

LH Profitability

Operating Margin

25.14%

Return on Equity

5.31%

Return on Assets

2.5%

Free Cashflow Yield

4.99%

LH Fundamentals

LH Revenue

Revenue (TTM)

12.2B

Rev. Growth (Yr)

-27.47%

Rev. Growth (Qtr)

-0.77%

LH Earnings

Earnings (TTM)

418.0M

Earnings Growth (Yr)

-319.58%

Earnings Growth (Qtr)

-191.16%

Breaking Down LH Revenue

52 Week Range

207.34

(Low)(High)

Last 7 days

3.1%

Last 30 days

-2.4%

Last 90 days

-6.8%

Trailing 12 Months

4.2%

How does LH drawdown profile look like?

LH Financial Health

Current Ratio

1.17

Debt/Equity

0.51

Debt/Cashflow

0.33

LH Investor Care

Buy Backs (1Y)

18.36%

Diluted EPS (TTM)

4.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.0B	11.4B	11.8B	12.2B
2022	9.6B	8.7B	7.5B	10.6B
2021	18.1B	19.2B	22.3B	13.1B
2020	10.9B	10.2B	9.5B	16.8B
2019	11.4B	11.4B	11.5B	11.6B
2018	10.7B	11.1B	11.3B	11.3B
2017	9.6B	9.7B	9.9B	10.3B
2016	16.5B	16.7B	16.8B	16.8B
2015	6.4B	7.1B	7.9B	8.7B
2014	10.4B	10.4B	10.5B	10.6B
2013	5.7B	5.7B	5.8B	5.8B
2012	5.6B	5.6B	5.6B	5.7B
2011	5.2B	5.3B	5.5B	5.5B
2010	4.7B	4.8B	4.9B	5.0B
2009	4.6B	4.6B	4.6B	4.7B
2008	0	4.2B	4.4B	4.5B
2007	0	0	0	4.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Laboratory Corp of America Holdings

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	eisenberg glenn a	acquired	-	-	10,229	chief financial officer, evp
Apr 15, 2024	eisenberg glenn a	sold (taxes)	-914,127	203	-4,496	chief financial officer, evp
Apr 01, 2024	summy amy b.	sold	-760,515	217	-3,500	evp, chief marketing officer
Apr 01, 2024	bailey megan d.	acquired	-	-	205	evp, chief strategy officer
Apr 01, 2024	schroeder mark s	sold	-1,407,390	217	-6,477	evp, pres diagnostics & coo
Apr 01, 2024	bailey megan d.	sold (taxes)	-14,928	216	-69.00	evp, chief strategy officer
Mar 28, 2024	van der vaart sandra d	sold	-770,077	216	-3,553	evp, chief legal officer
Mar 27, 2024	eisenberg glenn a	acquired	-	-	20,033	chief financial officer, evp
Mar 27, 2024	schechter adam h	sold (taxes)	-6,886,710	216	-31,799	president and ceo
Mar 27, 2024	berberian lance	sold (taxes)	-714,464	216	-3,299	evp, cio & cto

Which funds bought or sold LH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	0.9	-811,190	26,064,200	0.02%
Apr 22, 2024	WEYBOSSET RESEARCH & MANAGEMENT LLC	reduced	-1.54	-8,804,500	233,000	0.08%
Apr 22, 2024	Stonegate Investment Group, LLC	added	22.41	56,226	374,659	0.01%
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-5.95	278,532	4,683,540	0.03%
Apr 22, 2024	PARSONS CAPITAL MANAGEMENT INC/RI	reduced	-9.33	-95,820	649,919	0.04%
Apr 22, 2024	IFM Investors Pty Ltd	unchanged	-	-154,319	3,818,680	0.04%
Apr 22, 2024	Boston Trust Walden Corp	added	35.87	1,603,250	6,844,790	0.05%
Apr 22, 2024	Essex Savings Bank	unchanged	-	-	282,290	0.08%
Apr 22, 2024	MBL Wealth, LLC	added	0.01	-372,947	9,255,060	1.05%
Apr 22, 2024	SHIKIAR ASSET MANAGEMENT INC	reduced	-2.51	-28,000	424,000	0.12%

Are Funds Buying or Selling LH?

Are funds buying LH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LH

No. of Funds

LH Alerts

3 major insider sales recently.

Unveiling Laboratory Corp of America Holdings's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.48%	9,745,265	SC 13G/A
Jan 30, 2024	blackrock inc.	12.4%	10,488,875	SC 13G/A
Feb 10, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Feb 09, 2023	vanguard group inc	11.79%	10,450,115	SC 13G/A
Jan 26, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Jan 20, 2023	blackrock inc.	13.0%	11,474,507	SC 13G/A
Mar 09, 2022	blackrock inc.	10.4%	9,706,541	SC 13G/A
Feb 10, 2022	vanguard group inc	11.24%	10,753,065	SC 13G/A
Feb 01, 2022	blackrock inc.	8.6%	8,274,411	SC 13G/A
Feb 10, 2021	vanguard group inc	10.68%	10,405,602	SC 13G/A

Recent SEC filings of Laboratory Corp of America Holdings

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 11, 2024	8-K	Current Report
Apr 04, 2024	ARS	ARS
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Laboratory Corp of America Holdings)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-0.66%	-0.48%	39.62	7.35	-8.94%	-35.72%
IDXX	41.0B	3.7B	-6.96%	-1.95%	48.55	11.21	8.72%	24.44%
A	40.8B	6.7B	-5.62%	0.50%	33	6.06	-2.81%	-6.58%
DGX	15.1B	9.3B	5.76%	-6.69%	17.73	1.64	-6.38%	-9.73%
CRL	12.3B	4.1B	-11.91%	17.80%	25.98	2.99	3.86%	-2.39%
EXAS	11.5B	2.5B	2.30%	-4.05%	-56.49	4.61	19.93%	67.26%
MEDP	11.5B	2.0B	-0.40%	117.42%	36.88	5.87	25.57%	21.62%
NTRA	11.0B	1.1B	-1.39%	71.77%	-25.28	10.16	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-19.07%	-29.09%	1.7K	2.87	28.93%	111.61%
GH	2.1B	563.9M	0.58%	-24.79%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	426.1M	280.3M	-13.73%	-2.49%	-2.24	1.52	-12.89%	-148.37%
ACRS	86.5M	31.2M	6.09%	-86.56%	-0.98	2.77	5.03%	-1.81%
AWH	41.8M	9.2M	-7.12%	-37.22%	-2.51	4.57	11.85%	44.12%
APDN	4.9M	9.0M	-42.00%	-72.12%	-0.68	0.55	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Laboratory Corp of America Holdings News

Latest updates

Laboratory Corp of America Holdings Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.8%	3,033	3,057	3,034	3,608	4,182	2,867	2,923	640	1,071	4,063	3,841	4,162	10,220	947	2,769	2,824	2,953	2,918	2,882	2,835	2,788
Cost Of Revenue	-13.7%	1,904	2,206	2,192	2,803	1,829	1,981	1,981	2,667	328	2,677	2,576	2,563	2,585	2,337	2,008	2,096	2,133	2,111	2,057	2,002	2,015
Gross Profit	-10.8%	759	851	842	975	723	886	943	1,233	743	1,386	1,265	1,599	1,905	1,559	761	728	821	817	825	790	772
S&GA Expenses	-7.8%	485	526	506	554	434	453	432	464	282	520	459	430	518	420	396	396	414	402	415	394	397
Interest Expenses	-3.0%	49.00	50.00	50.00	51.00	49.00	46.00	42.00	42.00	43.00	42.00	78.00	49.00	48.00	51.00	53.00	55.00	64.00	61.00	59.00	57.00	58.00
Income Taxes	-64.8%	19.00	55.00	50.00	65.00	-35.65	38.00	92.00	148	75.00	180	183	252	304	243	65.00	49.00	66.00	66.00	79.00	69.00	384
Net Income	-191.2%	-167	183	189	213	76.00	353	359	492	553	587	467	770	938	703	232	-317	227	-317	190	186	158
Net Income Margin	-38.8%	0.03*	0.06*	0.06*	0.08*	0.09*	0.17*	0.17*	0.17*	0.15*	0.17*	0.18*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	141.7%	412	171	264	27.00	502	291	442	239	548	650	390	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.0%	16,725	16,886	17,719	20,200	20,155	19,826	20,403	20,728	20,385	20,867	20,417	20,417	20,072	18,740	17,849	17,298	18,046	17,848	17,744	16,971	16,185
Current Assets	-4.8%	3,765	3,954	5,121	4,695	4,625	4,372	5,031	5,230	5,331	6,021	5,694	5,638	5,125	4,086	3,413	2,891	2,981	2,988	2,849	2,885	2,835
Cash Equivalents	-26.3%	537	728	1,931	394	321	410	978	1,234	1,381	2,037	1,963	1,891	1,321	667	557	324	338	361	265	349	427
Inventory	2.9%	475	461	488	481	471	468	436	441	401	411	421	428	423	393	342	254	245	235	220	234	237
Net PPE	3.2%	2,912	2,821	2,762	2,944	2,794	2,885	2,870	2,808	2,815	2,692	2,702	2,697	2,730	2,609	2,628	2,610	2,637	2,463	2,544	2,458	1,740
Goodwill	-3.0%	6,143	6,332	6,182	8,116	6,124	8,218	8,114	8,166	5,891	7,907	7,745	7,721	7,752	7,614	7,423	7,389	7,865	7,815	7,844	7,386	7,360
Liabilities	-1.8%	8,835	8,994	8,914	9,839	10,040	9,715	9,982	9,987	10,091	10,321	10,151	10,375	10,614	10,481	10,477	10,260	10,459	10,597	10,580	9,840	9,195
Current Liabilities	11.2%	3,225	2,901	2,183	2,886	3,079	2,522	2,643	2,642	2,783	2,888	2,667	3,369	3,079	3,010	3,034	2,458	2,656	2,555	2,496	2,527	1,879
Long Term Debt	-8.4%	4,055	4,428	5,042	5,052	5,039	5,334	5,360	5,383	5,417	5,417	5,423	4,921	5,419	5,417	5,417	5,790	5,790	6,101	6,135	5,496	5,991
LT Debt, Non Current	-8.4%	4,055	4,428	5,042	5,052	5,039	5,334	5,360	5,383	5,417	5,417	5,423	4,921	5,419	5,417	5,417	5,790	5,790	6,101	6,135	5,496	5,991
Shareholder's Equity	0.0%	7,875	7,873	8,785	10,342	10,097	10,092	10,401	10,721	10,273	10,601	10,322	10,098	9,437	8,239	7,353	7,020	7,644	7,020	7,144	7,111	7,048
Retained Earnings	-2.2%	7,888	8,070	8,836	10,730	10,582	10,845	10,898	10,948	10,457	10,787	10,417	10,172	9,479	8,464	7,761	-	7,981	7,677	7,456	7,265	7,157
Additional Paid-In Capital	717.0%	38.00	5.00	94.00	48.00	-	-	-	29.00	-	-	-	67.00	110	81.00	32.00	-	27.00	48.00	91.00	1,401	1,451
Shares Outstanding	-100.0%	-	85.00	89.00	103	88.00	104	106	112	108	112	113	114	-	-	-	-	-	-	-	-	-
Float	-	-	-	17,300	-	-	-	20,200	-	-	-	24,800	-	-	-	15,200	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	110.4%	580	276	351	121	654	374	573	356	698	767	487	1,158	775	786	371	204	570	456	254	166	486
Share Based Compensation	-21.5%	27.00	34.00	27.00	41.00	24.00	30.00	26.00	38.00	21.00	59.00	24.00	29.00	27.00	27.00	40.00	18.00	24.00	32.00	27.00	26.00	21.00
Cashflow From Investing	32.2%	-330	-487	-253	-99.70	-273	-563	-242	-573	-254	-407	-90.40	-132	-128	-285	-123	-106	-152	-239	-750	-140	-146
Cashflow From Financing	59.3%	-446	-1,097	1,545	-60.60	-372	-452	-479	-17.70	-1,008	-281	-325	-450	-1.00	-396	-16.90	-102	-449	-115	415	-103	-802
Dividend Payments	-100.0%	-	64.00	65.00	64.00	-	65.00	67.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	-100.9%	-9.00	1,009	-	-	300	400	400	-	1,000	300	300	69.00	-34.25	69.00	-	100	275	100	200	100	400

LH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations [Abstract]
Revenues	$ 12,161.6	$ 11,863.9	$ 13,136.1
Cost of Revenue	8,796.7	8,155.0	8,143.7
Gross profit	3,364.9	3,708.9	4,992.4
Selling, general and administrative expenses	2,021.4	1,763.1	1,690.3
Amortization of intangibles and other assets	219.8	193.6	229.5
Goodwill and Intangible Asset Impairment	349.0	261.7	0.0
Restructuring and other special charges	49.1	54.0	24.0
Operating income	725.6	1,436.5	3,048.6
Interest expense	(199.6)	(179.8)	(211.8)
Equity method income, net	(1.4)	5.4	26.5
Investment income	28.8	7.5	8.8
Other, net	15.5	(32.2)	15.5
Provision for income taxes	188.5	233.9	690.0
Net earnings	419.2	1,280.6	2,379.5
Less: Net earnings attributable to the noncontrolling interest	(1.2)	(1.5)	(2.2)
Net earnings attributable to Laboratory Corporation of America Holdings	$ 418.0	$ 1,279.1	$ 2,377.3
Income (Loss) from Continuing Operations, Per Basic Share	$ 4.35	$ 11.00	$ 22.71
Earnings Per Share, Basic	$ 4.80	$ 14.05	$ 24.60
Income (Loss) from Continuing Operations Before Income Taxes and Noncontrolling Interest	$ 568.9	$ 1,237.4	$ 2,887.6
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	380.4	1,003.5	2,197.6
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 38.8	$ 277.1	$ 181.9
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share	$ 0.45	$ 3.04	$ 1.88
Income (Loss) from Continuing Operations, Per Diluted Share	4.33	10.94	22.52
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share	0.44	3.03	1.87
Earnings Per Share, Diluted	$ 4.77	$ 13.97	$ 24.39

LH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	12 Months Ended
CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Deferred Revenue, Revenue Recognized	$ 78,900,000	$ 99,700,000
Current assets:
Cash and Cash Equivalents, at Carrying Value	536,800,000	320,600,000
Accounts receivable, net	1,913,300,000	1,785,500,000
Unbilled Contracts Receivable	185,400,000	211,800,000
Supplies inventory	474,600,000	470,600,000
Prepaid expenses and other	655,300,000	610,400,000
Disposal Group, Including Discontinued Operation, Assets, Current	0	1,226,100,000
Total current assets	3,765,400,000	4,625,000,000
Property, plant and equipment, net	2,911,800,000	2,794,100,000
Goodwill, net	6,142,500,000	6,123,700,000
Intangible assets, net	3,342,000,000	3,123,600,000
Joint venture partnerships and equity method investments	26,900,000	65,700,000
Deferred Income Tax Assets, Net	0	6,400,000
Other assets, net	536,500,000	378,400,000
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0	3,038,200,000
Total assets	16,725,100,000	20,155,100,000
Current liabilities:
Finance Lease, Liability, Current	6,400,000	6,000,000.0
Accounts payable	827,500,000	852,200,000
Accrued expenses and other	804,000,000.0	787,000,000.0
Deferred Revenue, Current	421,700,000	310,600,000
Operating Lease, Liability, Current	165,800,000	163,800,000
Short-term borrowings and current portion of long-term debt	999,800,000	301,300,000
Disposal Group, Including Discontinued Operation, Liabilities, Current	0	657,600,000
Total current liabilities	3,225,200,000	3,078,500,000
Long-term debt, less current portion	4,054,700,000	5,038,800,000
Total maturities, due beyond one year	648,900,000	652,900,000
Total maturities, due beyond one year	78,600,000	83,600,000
Deferred income taxes and other tax liabilities	417,900,000	543,400,000
Other liabilities	409,300,000	401,100,000
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent	0	241,300,000
Total liabilities	8,834,600,000	10,039,600,000
Commitments and contingent liabilities
Noncontrolling interest	15,500,000	18,900,000
Shareholders’ equity
Common stock, 83.9 and 88.2 shares outstanding at December 31, 2023 and 2022, respectively	7,700,000	8,100,000
Additional paid-in capital	38,400,000	0
Retained earnings	7,888,200,000	10,581,700,000
Accumulated other comprehensive loss	(59,300,000)	(493,200,000)
Total shareholders’ equity	7,875,000,000	10,096,600,000
Total liabilities and shareholders’ equity	$ 16,725,100,000	20,155,100,000
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents		109,400,000
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net		436,500,000
Disposal Group, Including Discontinued Operation, Other Assets, Current		583,600,000
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current		96,600,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent		162,100,000
Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent		1,997,300,000
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent		823,300,000
Disposal Group, Including Discontinued Operation, Deferred Tax Assets		1,200,000
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent		54,300,000
Disposal Group, Including Discontinued Operation, Assets		4,264,300,000
Disposal Group, Including Discontinued Operation, Accounts Payable, Current		82,600,000
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current		281,800,000
Disposal Group, Including Discontinued Operation, Deferred Revenue, Current		271,500,000
Disposal Group, Including Discontinued Operation, Short-term operating lease liabilities		21,700,000
Disposal Group, Including Discontinued Operation, Operating lease liabilities		26,800,000
Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable, Noncurrent		192,800,000
Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent		21,700,000
Disposal Group, Including Discontinued Operation, Liabilities		$ 898,900,000

About Laboratory Corp of America Holdings

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

CEO	Mr. Adam H. Schechter
WEBSITE	labcorp.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	60000

Laboratory Corp of America Holdings Frequently Asked Questions

What is the ticker symbol for Laboratory Corp of America Holdings? What does LH stand for in stocks?

LH is the stock ticker symbol of Laboratory Corp of America Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Laboratory Corp of America Holdings (LH)?

As of Tue Apr 23 2024, market cap of Laboratory Corp of America Holdings is 17.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers.

What is the fair value of LH stock?

You can check LH's fair value in chart for subscribers. The fair value of Laboratory Corp of America Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Laboratory Corp of America Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Laboratory Corp of America Holdings a good stock to buy?

The fair value guage provides a quick view whether LH is over valued or under valued. Whether Laboratory Corp of America Holdings is cheap or expensive depends on the assumptions which impact Laboratory Corp of America Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LH.

What is Laboratory Corp of America Holdings's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, LH's PE ratio (Price to Earnings) is 41.87 and Price to Sales (PS) ratio is 1.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Laboratory Corp of America Holdings's stock?

In the past 10 years, Laboratory Corp of America Holdings has provided 0.093 (multiply by 100 for percentage) rate of return.